Pfizer
Darjan Duraki is a Principal Scientist at Pfizer, having transitioned from a Senior Scientist role, and has extensive research experience from positions at the University of Illinois Urbana-Champaign and the University of Illinois Chicago. In the David Shapiro Lab, Duraki contributed significantly to the preclinical development of a first-in-class a-UPR activator, ErSO, targeting therapy-resistant breast cancers and conducted lead development for compounds aimed at estrogen receptor-positive cancers. Key responsibilities included evaluating cytotoxicity, determining mechanisms of action, generating stable cell line models, creating xenograft models for various cancers, and conducting high-throughput screening for SARS-CoV-2 inhibitors. Earlier experience included synthesizing naphthoquinones relevant to Ebola virus research in the Duncan Wardrop Lab. Duraki holds a PhD in Biochemistry from the University of Illinois Urbana-Champaign and a Bachelor's degree in Biochemistry from the University of Illinois Chicago.
This person is not in any teams
This person is not in any offices
Pfizer
582 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.